Cognition Therapeutics (CGTX)

• Market cap: $98.9M
• 1 day: 4.67%
• 5 days: 5.66%
• 1 month: -21.68%
• 3 months: -27.27%
• 6 months: -8.2%
• Year to date: -23.81%
• 1 year: 89.83%
• 5 years: -91.23%
• 10 years: -91.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25